Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CHRS
stocks logo

CHRS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.44M
-73.33%
-0.310
+10.71%
17.96M
-54.81%
-0.290
-17.14%
38.35M
+274.04%
-0.290
-14.71%
Estimates Revision
The market is revising Downward the revenue expectations for Coherus Oncology, Inc. (CHRS) for FY2025, with the revenue forecasts being adjusted by -5.29% over the past three months. During the same period, the stock price has changed by -4.65%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.53%
In Past 3 Month
Stock Price
Go Down
down Image
-4.65%
In Past 3 Month
Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.230
sliders
Low
4.00
Averages
5.50
High
7.00
Current: 1.230
sliders
Low
4.00
Averages
5.50
High
7.00
Maxim
Jason McCarthy
Hold
to
Buy
upgrade
2025-09-04
Reason
Maxim
Jason McCarthy
Price Target
2025-09-04
upgrade
Hold
to
Buy
Reason
Maxim analyst Jason McCarthy upgraded Coherus Biosciences to Buy from Hold.
UBS
Ashwani Verma
Neutral
downgrade
2025-04-24
Reason
UBS
Ashwani Verma
Price Target
2025-04-24
downgrade
Neutral
Reason
UBS analyst Ashwani Verma lowered the firm's price target on Coherus Biosciences to $1.05 from $1.50 and keeps a Neutral rating on the shares.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$7
2025-03-11
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$7
2025-03-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$7
2025-01-23
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$7
2025-01-23
Reiterates
Strong Buy
Reason
Baird
Colleen Kusy
Buy
Maintains
$4 → $6
2024-12-05
Reason
Baird
Colleen Kusy
Price Target
$4 → $6
2024-12-05
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Coherus Oncology Inc (CHRS.O) is -1.74, compared to its 5-year average forward P/E of -7.59. For a more detailed relative valuation and DCF analysis to assess Coherus Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.59
Current PE
-1.74
Overvalued PE
1.43
Undervalued PE
-16.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-15.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
47.62
Undervalued EV/EBITDA
-77.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.04
Current PS
0.00
Overvalued PS
3.24
Undervalued PS
0.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CHRS News & Events

Events Timeline

(ET)
2025-11-07
09:19:36
Coherus Biosciences Reveals Results from Phase 1b Trial of CHS-114
select
2025-11-06 (ET)
2025-11-06
17:21:29
Coherus Biosciences announces Q3 earnings per share of 33 cents, surpassing consensus estimate of 29 cents.
select
2025-08-07 (ET)
2025-08-07
16:55:05
Coherus Biosciences reports Q2 EPS (39c), consensus (27c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-07Newsfilter
Coherus Oncology Showcases Multiomic Biomarker Data for CHS-114, a Selective Anti-CCR8 Cytolytic Antibody, at SITC Conference

  • CHS-114 Clinical Trial Results: Coherus Oncology's CHS-114, an anti-CCR8 antibody, showed effective depletion of CCR8+ Tregs and increased CD8 T cells in head and neck squamous cell carcinoma (HNSCC) patients, indicating promising immune remodeling and antitumor activity.

  • Combination Therapy with Toripalimab: The combination of CHS-114 with toripalimab resulted in enhanced immune activation and a significant increase in CD8+ T cell proliferation, supporting further development of this treatment strategy in advanced solid tumors.

  • Safety Profile and Efficacy: The ongoing Phase 1b trial demonstrated a manageable safety profile for CHS-114, with early signs of antitumor activity, including a partial response in a refractory HNSCC patient.

  • Future Development Plans: Coherus aims to optimize dosing for CHS-114 in combination with toripalimab, addressing FDA's Project Optimus and advancing to Phase 2 trials based on the promising results from the current study.

[object Object]
Preview
9.5
11-07NASDAQ.COM
Coherus Oncology (CHRS) Posts Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Coherus Oncology reported a quarterly loss of $0.33 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.32, and significantly down from a loss of $0.01 per share a year ago.

  • Revenue Miss: The company generated revenues of $11.57 million for the quarter, missing the consensus estimate by 5.23% and down from $70.77 million in the same quarter last year.

  • Stock Outlook: Coherus Oncology's stock has underperformed compared to the S&P 500 this year, and its future performance will depend on management's commentary and earnings estimate revisions, currently holding a Zacks Rank #3 (Hold).

  • Industry Context: The Medical - Biomedical and Genetics industry is ranked in the top 41% of Zacks industries, indicating potential for better performance, while another industry peer, Armata Pharmaceuticals, is expected to report a significant loss in its upcoming results.

[object Object]
Preview
1.0
10-23Newsfilter
Coherus Oncology to Attend Upcoming Investor Conferences

  • Upcoming Conferences: Coherus Oncology will webcast presentations at the UBS Global Healthcare Conference on November 10, 2025, the Jefferies Global Healthcare Conference on November 18, 2025, and the Baird Biotech Discovery Series on December 17, 2025, with replays available for 30 days.

  • Company Overview: Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of mid-stage clinical candidates targeting various cancers, aiming to grow sales and develop new indications.

  • Innovative Pipeline: The company's pipeline includes antibody immunotherapy candidates like CHS-114, currently in Phase 1b/2a studies, and Casdozokitug, being evaluated in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors.

  • Disclosure Practices: Coherus utilizes its website for disclosing material non-public information and complies with Regulation FD, ensuring transparency with investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Coherus Oncology Inc (CHRS) stock price today?

The current price of CHRS is 1.23 USD — it has increased 0.82 % in the last trading day.

arrow icon

What is Coherus Oncology Inc (CHRS)'s business?

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

arrow icon

What is the price predicton of CHRS Stock?

Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Coherus Oncology Inc (CHRS)'s revenue for the last quarter?

Coherus Oncology Inc revenue for the last quarter amounts to 11.57M USD, increased 91.19 % YoY.

arrow icon

What is Coherus Oncology Inc (CHRS)'s earnings per share (EPS) for the last quarter?

Coherus Oncology Inc. EPS for the last quarter amounts to -0.31 USD, increased 244.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for Coherus Oncology Inc (CHRS)'s fundamentals?

The market is revising Downward the revenue expectations for Coherus Oncology, Inc. (CHRS) for FY2025, with the revenue forecasts being adjusted by -5.29% over the past three months. During the same period, the stock price has changed by -4.65%.
arrow icon

How many employees does Coherus Oncology Inc (CHRS). have?

Coherus Oncology Inc (CHRS) has 228 emplpoyees as of December 05 2025.

arrow icon

What is Coherus Oncology Inc (CHRS) market cap?

Today CHRS has the market capitalization of 148.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free